Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 23 min ago
Peer-reviewedCC BY-NCJournal of Dermatological Treatment

Unveiling the IL-17 axis: an immunometabolic bridge between psoriasis and metabolic syndrome

  • Paolo Gisondi1
  • Zeno Fratton2
  • Ralph Vighi da Rosa3
  • Vittoria Bellini1
  • Andrea Carugno4
4 affiliations
  1. 1Department of Medicine Section of Dermatology and Venereology, University of Verona
  2. 2Department of Medicine, Institute of Dermatology, University of Udine
  3. 3Universidade Católica de Pelotas (UCPel)
  4. 4Department of Medicine and Surgery, University of Insubria
Open at sourceDOICite

Abstract

AIM OF THE REVIEW: Psoriasis is increasingly recognized as a systemic inflammatory disease frequently associated with a cluster of cardiometabolic comorbidities, including obesity, type 2 diabetes, and cardiovascular disease. Central to this association is the interleukin-17 (IL-17) signaling axis, a key driver of both cutaneous inflammation and systemic metabolic dysfunction. MATERIALS AND METHODS: This review examines the complex immunometabolic interactions mediated by IL-17 and synergistic cytokines such as TNF‑α, IL‑6, IL‑1β, IL‑23, and adipokines, which contribute to endothelial dysfunction, insulin resistance, and adipose-tissue inflammation. RESULTS: Beyond its established role in psoriasis pathogenesis, the IL-17 pathway is implicated in the 'psoriatic march,' linking chronic skin inflammation to accelerated atherosclerosis. The advent of IL-17 inhibitors has transformed the management of moderate-to-severe psoriasis, achieving unprecedented skin clearance (PASI 90/100). Emerging evidence suggests that these agents may also exert potential beneficial effects on selected inflammatory and cardiometabolic markers. However, their direct impact on metabolic parameters remains under investigation. CONCLUSION: Understanding these shared molecular pathways is essential for adopting a holistic therapeutic approach that addresses both cutaneous disease and the systemic burden of psoriatic patients.

Related

  1. Immunometabolic synaptopathy: linking metabolic syndrome to epileptogenesis through trained immunity and parvalbumin interneuron vulnerability
    Baihui Zhang, Wenjin Wang, Tao Li +1
    Frontiers in cellular neurosciencePeer-reviewedCC BYFull textNeuroscienceEurope PMC
  2. Shared genetic basis and spatial cellular atlas of psoriasis and metabolic syndrome
    Guo Liu, Fengjuan Gong, Guanhu Yang +5
    PLOS OnePeer-reviewedCC BY 4.0Full textGenetics & genomicsPLOS
  3. Mitochondria as immunometabolic hubs in psoriasis: pathogenic mechanisms and therapeutic prospects
    Fangru Zhao, Yaoxing Guo, Xin Tong +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefDOAJ
  4. Pathophysiology-guided nutritional strategies for persistent inflammation, immunosuppression, and catabolism syndrome: an immunometabolic perspective
    Zhiyang Wu, Bo Yao
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMCPMC
  5. Immune-cell imbalance and immunometabolic reprogramming in chronic prostatitis/chronic pelvic pain syndrome
    Hao Li, Andong Cheng, Mengfan Wang +7
    Frontiers in immunologyPeer-reviewedCC BYFull text1 citedImmunologyEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{gisondi2026unveiling,
  title = {{Unveiling the IL-17 axis: an immunometabolic bridge between psoriasis and metabolic syndrome}},
  author = {Paolo Gisondi and Zeno Fratton and Ralph Vighi da Rosa and Vittoria Bellini and Andrea Carugno},
  journal = {Journal of Dermatological Treatment},
  year = {2026},
  month = jun,
  doi = {10.1080/09546634.2026.2673285},
  url = {https://doi.org/10.1080/09546634.2026.2673285},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Unveiling the IL-17 axis: an immunometabolic bridge between psoriasis and metabolic syndrome
AU  - Paolo Gisondi
AU  - Zeno Fratton
AU  - Ralph Vighi da Rosa
AU  - Vittoria Bellini
AU  - Andrea Carugno
PY  - 2026
DA  - 2026/06/01
JO  - Journal of Dermatological Treatment
DO  - 10.1080/09546634.2026.2673285
UR  - https://doi.org/10.1080/09546634.2026.2673285
AB  - AIM OF THE REVIEW: Psoriasis is increasingly recognized as a systemic inflammatory disease frequently associated with a cluster of cardiometabolic comorbidities, including obesity, type 2 diabetes, and cardiovascular disease. Central to this association is the interleukin-17 (IL-17) signaling axis, a key driver of both cutaneous inflammation and systemic metabolic dysfunction. MATERIALS AND METHODS: This review examines the complex immunometabolic interactions mediated by IL-17 and synergistic cytokines such as TNF‑α, IL‑6, IL‑1β, IL‑23, and adipokines, which contribute to endothelial dysfunction, insulin resistance, and adipose-tissue inflammation. RESULTS: Beyond its established role in psoriasis pathogenesis, the IL-17 pathway is implicated in the 'psoriatic march,' linking chronic skin inflammation to accelerated atherosclerosis. The advent of IL-17 inhibitors has transformed the management of moderate-to-severe psoriasis, achieving unprecedented skin clearance (PASI 90/100). Emerging evidence suggests that these agents may also exert potential beneficial effects on selected inflammatory and cardiometabolic markers. However, their direct impact on metabolic parameters remains under investigation. CONCLUSION: Understanding these shared molecular pathways is essential for adopting a holistic therapeutic approach that addresses both cutaneous disease and the systemic burden of psoriatic patients.
SN  - 0954-6634
SN  - 1471-1753
ER  -